Literature DB >> 24178973

Principles of separation: indications and therapeutic targets for plasma exchange.

Mark E Williams1, Rasheed A Balogun.   

Abstract

Extracorporeal "blood purification," mainly in the form of hemodialysis has been a major portion of the clinical activity of many nephrologists for the past 5 decades. A possibly older procedure, therapeutic plasma exchange, separates and then removes plasma as a method of removing pathogenic material from the patient. In contrast to hemodialysis, therapeutic plasma exchange preferentially removes biologic substances of high molecular weight such as autoantibodies or alloantibodies, antigen-antibody complexes, and Ig paraproteins. These molecular targets may be cleared through two alternative procedures: centrifugal separation and membrane separation. This review presents operational features of each procedure, with relevance to the nephrologist. Kinetics of removal of these plasma constituents are based on the principles of separation by the apheresis technique and by features specific to each molecular target, including their production and compartmentalization in the body. Molecular targets for common renal conditions requiring therapeutic plasma exchange are also discussed in detail.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24178973      PMCID: PMC3878701          DOI: 10.2215/CJN.04680513

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  57 in total

Review 1.  Introduction and overview of therapeutic apheresis.

Authors:  Chidi Okafor; David M Ward; Michele H Mokrzycki; Robert Weinstein; Pamela Clark; Rasheed A Balogun
Journal:  J Clin Apher       Date:  2010       Impact factor: 2.821

Review 2.  Therapeutic apheresis: history, clinical application, and lingering uncertainties.

Authors:  Bruce C McLeod
Journal:  Transfusion       Date:  2009-11-20       Impact factor: 3.157

3.  Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients.

Authors:  R Y Gohh; A F Yango; P E Morrissey; A P Monaco; A Gautam; M Sharma; E T McCarthy; V J Savin
Journal:  Am J Transplant       Date:  2005-12       Impact factor: 8.086

4.  Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study.

Authors:  Zhao Cui; Juan Zhao; Xiao-Yu Jia; Sai-Nan Zhu; Qi-Zhuang Jin; Xu-Yang Cheng; Ming-Hui Zhao
Journal:  Medicine (Baltimore)       Date:  2011-09       Impact factor: 1.889

5.  Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia.

Authors:  E M Berkman; J B Orlin
Journal:  Transfusion       Date:  1980 Mar-Apr       Impact factor: 3.157

6.  A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; S P Lan; R D Rohde; J M Lachin
Journal:  N Engl J Med       Date:  1992-05-21       Impact factor: 91.245

7.  Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury.

Authors:  Xiao-yu Jia; Zhao Cui; Rui Yang; Shui-yi Hu; Ming-hui Zhao
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-29       Impact factor: 8.237

Review 8.  Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Ellen T McCarthy; Mukut Sharma; Virginia J Savin
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-21       Impact factor: 8.237

9.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

10.  Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations.

Authors:  Gunnar Tydén; Johannes Donauer; Jonas Wadström; Gunilla Kumlien; Jochen Wilpert; Thomas Nilsson; Helena Genberg; Przemislaw Pisarski; Gunnar Tufveson
Journal:  Transplantation       Date:  2007-05-15       Impact factor: 4.939

View more
  13 in total

1.  Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Authors:  Lidia Stork; David Ellenberger; Tim Beißbarth; Tim Friede; Claudia F Lucchinetti; Wolfgang Brück; Imke Metz
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

2.  Heterogeneity of cultured melanocyte elongation and proliferation factor in bilateral diffuse uveal melanocytic proliferation.

Authors:  Jeremy A Lavine; Michael S Ramos; Alyson M Wolk; Kimberly Baynes; Sumit Sharma; Aleksandra V Rachitskaya; Bela Anand-Apte; Sunil K Srivastava; Alex Yuan
Journal:  Exp Eye Res       Date:  2019-04-10       Impact factor: 3.467

3.  Hemolytic uremic syndrome in a developing country: Consensus guidelines.

Authors:  Arvind Bagga; Priyanka Khandelwal; Kirtisudha Mishra; Ranjeet Thergaonkar; Anil Vasudevan; Jyoti Sharma; Saroj Kumar Patnaik; Aditi Sinha; Sidharth Sethi; Pankaj Hari; Marie-Agnes Dragon-Durey
Journal:  Pediatr Nephrol       Date:  2019-04-15       Impact factor: 3.714

Review 4.  Therapeutic apheresis in kidney diseases: an updated review.

Authors:  Yi-Yuan Chen; Xin Sun; Wei Huang; Fang-Fang He; Chun Zhang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 5.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

6.  Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome.

Authors:  Priyanka Khandelwal; Aarti Gupta; Aditi Sinha; Savita Saini; Pankaj Hari; Marie-Agnes Dragon Durey; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2014-09-13       Impact factor: 3.714

Review 7.  Therapeutic plasma exchange in children with acute liver failure (ALF): is it time for incorporation into the ALF armamentarium?

Authors:  Emma C Alexander; Akash Deep
Journal:  Pediatr Nephrol       Date:  2021-10-14       Impact factor: 3.651

8.  Effect of therapeutic plasma exchange on plasma levels and total removal of adipokines and inflammatory markers.

Authors:  Julius J Schmidt; Janine Jahn; Jan T Kielstein; Heike Kielstein; Paulina Golla; Carsten Hafer
Journal:  BMC Obes       Date:  2015-09-30

9.  Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic.

Authors:  Rocio Lledo-Garcia; Kate Dixon; Anthony Shock; Ruth Oliver
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-11-23

10.  Description of the Use of Plasma Exchange in Dogs With Cutaneous and Renal Glomerular Vasculopathy.

Authors:  Ragnhild Skulberg; Stefano Cortellini; Daniel L Chan; Giacomo Stanzani; Rosanne E Jepson
Journal:  Front Vet Sci       Date:  2018-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.